Experience

Jalon Therapeutics
• France
• Biotechnology Research
• 1 - 100 Employee
• Executive Chairman - Co-Founder

  • Jan 2021 - Present


NOCOLEM

• France
• Research Services

• Président

  • Jan 2019 - Present

  Consulting boutique over-sighting and managing of multiple areas of drug development, including CMC toxicology, PK, drug non clinical demonstration, translational scientific research and clinical & regulatory operations up to early (Phase I & II) clinical phases. Set overall department and project goals, timelines, resource requirements and budgets, resulting in meeting corporate goals in a fast-paced environment Consulting boutique over-sighting and managing of multiple areas of drug development, including CMC toxicology, PK, drug non clinical demonstration, translational scientific research and clinical & regulatory operations up to early (Phase I & II) clinical phases. Set overall department and project goals, timelines, resource requirements and budgets, resulting in meeting corporate goals in a fast-paced environment



Our Future Universe

• France
• IT Services and IT Consulting
• 1 - 100 Employee

• Chairman & Co-Founder

  • Jan 2019 - Sep 2022

  Our Future Universe (OFU) is a UFO in the media landscape. Combining content curation and investigative journalism; texts, images and sounds, OFU will offer professionals (researchers, clinicians, industrials, teachers and students) and key players (analysts, journalists, institutions and of course patients) in biomedical innovation a first-in-class information digital platform to easily keep up to date with the latest research and news and go deeper in their fields Our Future Universe (OFU) is a UFO in the media landscape. Combining content curation and investigative journalism; texts, images and sounds, OFU will offer professionals (researchers, clinicians, industrials, teachers and students) and key players (analysts, journalists, institutions and of course patients) in biomedical innovation a first-in-class information digital platform to easily keep up to date with the latest research and news and go deeper in their fields



Innate Pharma

• France
• Biotechnology Research
• 100 - 200 Employee

• EVP Chief Development Officer

  • Oct 2009 - Dec 2018

  In charge of the global responsibility of Product Development : overseeing CMC, Regulatory Non clinical and Clinical operations teams. Jerome acts also as Board member of the Platine Pharma Services (Lyon, France), the immunomonitoring subsidiary of Innate.

• President IPH Inc

  • Jan 2008 - Dec 2018

  After 6 years in charge of Development and Operations in the company, Jérôme started Innate Pharma Inc the US subsidiary begining of 2008. He currently holds the position of President of Innate Pharma Inc.

• EVP Developpement & Operations

  • 2001 - 2008

  Jérôme joined Innate Pharma on September 2001. He was overseing the CMC, preclinical and global Program management of the main R&D program of the company.



Imtix Sangstat (then Genzyme Polyclonals then Sanofi)

• Director, European R & D

  • Oct 1997 - 2001

  End of 1997, Jerome moved to Pasteur-Mérieux IMTIX Transplant business unit (which was acquired by Sangstat and then Genzyme) as Preclinical Director (1997-1999) and European R&D Director (1999-2001). He managed different pharmaceutical product licenses pre-clinical development (antithymocyte polyclonal antibodies: Thymoglobulin, and mAb anti-LFA1) as well as new molecule research projects End of 1997, Jerome moved to Pasteur-Mérieux IMTIX Transplant business unit (which was acquired by Sangstat and then Genzyme) as Preclinical Director (1997-1999) and European R&D Director (1999-2001). He managed different pharmaceutical product licenses pre-clinical development (antithymocyte polyclonal antibodies: Thymoglobulin, and mAb anti-LFA1) as well as new molecule research projects



IMEDEX (spin-off Pasteur Merieux)

• Manager Product Development

  • 1986 - 1997

  Jerome Tiollier started working with Imedex SA (1986-1997), a French biotech spin-off from Institut Mérieux (now Sanofi Pasteur) where he managed the development of different biological products from preclinical to early clinical stages (phase I/II) in the field of biomaterials and therapeutic protein with internal R & D groups & CROs within partnership with European and US based companies. Jerome Tiollier started working with Imedex SA (1986-1997), a French biotech spin-off from Institut Mérieux (now Sanofi Pasteur) where he managed the development of different biological products from preclinical to early clinical stages (phase I/II) in the field of biomaterials and therapeutic protein with internal R & D groups & CROs within partnership with European and US based companies.